

# EMI LAUNCH EVENT

WEDNESDAY, 18 MAY 2016  
HOROBIN ROOM, HOMERTON COLLEGE

---



Cambridge University Hospitals   
NHS Foundation Trust

Cambridge Biomedical Research Centre

  
MHS  
National Institute for  
Health Research

AstraZeneca 

 gsk  
GlaxoSmithKline

 MedImmune

## EXPERIMENTAL MEDICINE TRAINING INITIATIVE – AGENDA

2:00 – 2:15	<b>Registration</b>	<b>Bamford and Skillicorn Room</b>
2:15-2:25	<b>Welcome</b> Opening remarks by Professor Tim Eisen	<b>Horobin Room</b> <b>Chair: Professor Tim Eisen</b>
2:25-2:55	<b>Keynote Speaker</b> Dr Barry Rosen – AZ VP and Senior Scientist 'Precise Genome Editing and Stem Cell Technologies: Novel Tools for Novel Medicines' Q & A	
2:55-3:25	<b>Short Talks: EMI Vision</b> Prof Ian Wilkinson - University of Cambridge (EMIT) 'An overview of EMI training' Prof Tim Eisen - AZ/MedImmune Dr Danielle Gerlag – GSK Q & A	<b>Chair: Dr David Howe</b>
3:25-4:00	<b>Break with refreshments &amp; Networking</b>	<b>Combination Room</b>

4:00-5:00

**Short Talks: EMI Science**

Dr Simon Pacey – University of Cambridge  
(Oncology)

Dr Joseph Cheriyan – Cambridge BioMedical  
Campus

Dr Yamamoto - AZ/MedImmune, PhD Student

'Developing a quantitative systems model for use  
in translational safety'

Q & A

5:00-5:45

**Short Talks: EMI Science**

Dr Elizabeth Wlodek – GSK, PhD Student

'Investigating the role of interleukin 18 in  
ischaemia re-perfusion injury in human kidneys'

Dr James MacKay – GSK, PhD Student

'Multiparametric MR Imaging of Osteoarthritis  
for Experimental Medicine Studies'

Dr Phil Ambery - AZ/MedImmune 'Towards Novel  
Treatments for Diabetes and Heart Failure'

Q & A

5:45-6:00

**Final Remarks**

Prof Tim Eisen, Prof Ian Wilkinson and Dr Danielle  
Gerlag

6:00-6:45

**Poster session & Networking  
Refreshments and canapés**

**Bamford and  
Skillicorn Room**

## BIOGRAPHIES IN ALPHABETICAL ORDER

### **Dr Phil Ambery** **Senior Director, Clinical Biologics, Medimmune**



Phil has considerable experience across all phases of clinical development in cardiovascular and metabolic diseases (CVMD) in the pharmaceutical industry. Having worked in medical affairs, late phase and early phase development for GSK from 2001-2014, he joined Medimmune where he is the lead member for the CVMD clinical group in Cambridge. He has a particular interest in incretins for the treatment of Type 2 diabetes and in Type 1 diabetes immune modulation. He is a specialist partner for the General Medical Council in academic or research certification, taking a particular interest in the licensing of doctors via the academic route, and still practises as an Acute Medicine Physician in Addenbrookes.

Email: [amberyp@MedImmune.com](mailto:amberyp@MedImmune.com)

### **Dr Joseph Cheriyan** **Consultant Physician & Clinical Pharmacologist at Addenbrooke's Hospital,** **Associate Lecturer, University of Cambridge, Director of the Cardiovascular Trials** **Office, Vice Chair of the Cambridge Research Ethics Committee**



Joseph is an active clinical researcher with interests in cardiovascular medicine particularly vascular function and inflammation and is uniquely the only MHRA accredited Phase I/II clinical trialist on the Cambridge Biomedical Campus working on early phase experimental medicine studies since 2006. His post combines NHS research within a University Department, in close collaboration with GSK's only remaining in house Clinical Unit, where he is seconded as a Senior Clinical Pharmacologist.

Email: [jc403@medschl.cam.ac.uk](mailto:jc403@medschl.cam.ac.uk)

## **Professor Tim Eisen**

### **Professor of Medical Oncology, Chief Clinician Scientist of AstraZeneca**



Tim completed his basic medical training at the University of Cambridge School of Medicine. Between 1991 and 1995 he was a clinical research fellow at the Marie Curie Research Institute in Surrey. During this time he completed a PhD on the molecular biology of melanoma. Following this he trained as a medical oncologist on the Senior Registrar rotation of the Royal Marsden Hospital, London and Surrey and received his Certificate of Completion of Specialist Training in Medical Oncology in 1997.

In 1998 he was appointed as Senior Lecturer in Medical Oncology at University College London. In February 2001 he took up a new post as Senior lecturer in Medical Oncology at the Institute of Cancer Research and the Royal Marsden Hospital. In October 2006 he took up a new post as Professor of Medical Oncology in the University of Cambridge. Since September 2014, he has been on leave of absence from the University of Cambridge to work 4 days per week as Chief Clinician Scientist of AstraZeneca; he continues to work on the treatment and research of kidney cancer for the rest of his working week. Tim is a fellow of the Royal College of Physicians.

Email: [TimothyG.Eisen@astrazeneca.com](mailto:TimothyG.Eisen@astrazeneca.com)

## **Dr Danielle Gerlag**

### **Head, Clinical Trial Unit Cambridge (CUC)**



Daniëlle Gerlag, MD PhD, is the head of the CUC since September 2013. She came from an academic background being an associate professor at the Division of Clinical Immunology and Rheumatology EULAR & FOCIS Centre of Excellence Academic Medical Centre/University of Amsterdam in The Netherlands, where she headed up the clinical trial team performing early phase experimental medicine studies in inflammatory joint diseases for about 10 years. As head of the CUC she and her team focus on performing experimental medicine studies in early drug development to help bring down attrition rates by learn about the pathogenesis of disease and the effects of the compounds studied.

Email: [danielle.x.gerlag@gsk.com](mailto:danielle.x.gerlag@gsk.com)

**Dr Jamie MacKay**  
**Clinical PhD student, EMI/GSK**



Jamie is a clinical radiologist interested in a variety of musculoskeletal conditions, particularly osteoarthritis (OA). His research to date has focussed on assessment of subchondral bone and osteochondral junction in knee OA using novel magnetic resonance (MR) imaging acquisition and analysis techniques. His PhD research will focus on the development of novel MR techniques for use in experimental medicine studies of OA.

Email: [jwm37@cam.ac.uk](mailto:jwm37@cam.ac.uk)

**Dr Simon Pacey**  
**Academic Training Lead and Urology Research Lead, Academic Consultant in Experimental Cancer Therapeutics**



Simon has a research interest in novel drug development and runs a portfolio of early phase clinical studies for patients. One key focus is on early Prostate cancer through collaborations with Astra Zeneca/ Medimmune to study the effects of novel drugs and drug combinations in pre-clinical models, specifically the mTOR inhibitor (AZD2014). He is Chief Investigator for the “CANCAP” clinical trials program, which study the molecular pharmacology of novel drugs prior to radical prostatectomy. He is co-lead for the urology clinical trials program and has recently taken the role of academic speciality training lead for Medical Oncology.

Email: [simonpacey@medschl.cam.ac.uk](mailto:simonpacey@medschl.cam.ac.uk)

## **Dr Barry Rosen**

**Senior Principal Scientist / Director, AstraZeneca Discovery Sciences, Cambridge**



Barry is responsible for the development and application of technologies in the area of precision genome engineering, human stem cell based disease models and transgenics in Discovery Sciences at AstraZeneca and the facilitating the exploitation of these technologies by our iMED disease focus areas for their drug discovery activities. He previously worked for many years at the Wellcome Trust Sanger Institute where he was involved in the generation of the large scale targeted mouse knockout resources of the IKMC and the IMPC and the generation of bespoke mouse and human stem cell models.

Barry did his PhD at Harvard Medical School on adipocyte molecular biology and his postdoctoral work in Edinburgh on mouse molecular embryology. He also is a founding instructor of the annual Wellcome Trust Advanced Course in Genome Engineering of Mammalian Stem Cells held at the Sanger.

Email: [barry.rosen@astrazeneca.com](mailto:barry.rosen@astrazeneca.com)

## **Professor Ian Wilkinson**

**Professor of Therapeutics, Director of Cambridge Clinical Trials' Unit, Director of the Office of Translational Research**



Ian has a long track record in clinical pharmacology and arterial haemodynamics. His research interest is in clinical/experimental studies designed to understand the mechanisms underlying arteriosclerosis and cardiovascular disease, and to understand the importance of novel biomarkers of arterial function in risk prediction. He directs the Cambridge Clinical Trials' Unit and is also a director of the Office of Translational Research in Cambridge. He has considerable experience of translational research, and in forming academic collaborations with Industry.

Email: [ibw20@medschl.cam.ac.uk](mailto:ibw20@medschl.cam.ac.uk)


**Dr Elizabeth Wlodek**  
**Clinical PhD Student, EMI/GSK**



Elizabeth graduated with an MBBS and BMedSci in Molecular Medicine from Barts and the London School of Medicine and Dentistry in London. She then undertook Academic Foundation Training, with a research post in Virology at the Royal Free Hospital where she studied the role of IL28B SNPs in response to HIV treatment. She continued her medical training as an NIHR funded Academic Clinical Fellow in Surgery at Addenbrooke's Hospital, Cambridge, where she investigated the role of CD8 T cells in graft rejection. She is currently an EMI/ACT funded PhD student at the University of Cambridge, her research is focused on the role of inflammasome products in ischaemia-reperfusion injury in human kidneys

Email: [ew418@cam.ac.uk](mailto:ew418@cam.ac.uk)

**Dr Takahiro Yamamoto**  
**Clinical PhD Student, EMI/AstraZeneca**



Takahiro started his Clinical PhD with EMIT and Translational Safety at AstraZeneca in January 2016. He is a Clinical Pharmacology and Therapeutics trainee and was based at Guy's and St Thomas' Hospitals with the Clinical Toxicology department prior to commencing his studentship. His research interests include the cardiovascular effects of drugs and the current research project aims to generate unique human cardiovascular haemodynamic data which will be used to build quantitative PKPD systems models of the human cardiovascular system in health and disease.

Email: [ty288@cam.ac.uk](mailto:ty288@cam.ac.uk)

## ATTENDEE LIST

